Cited by 1,828Substance Abuse Treatment and OutcomesAlcohol Consumption and Health EffectsAlcoholism and Thiamine Deficiency

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Naltrexone in the Treatment of Alcohol Dependence

Volpicelli, Joseph R.·1992·Archives of General Psychiatry

DOI 10.1001/archpsyc.1992.01820110040006

Open this paper in CoChat — free account

Abstract

Seventy male alcohol-dependent patients participated in a 12-week, double-blind, placebo-controlled trial of naltrexone hydrochloride (50 mg/d) as an adjunct to treatment following alcohol detoxification. Subjects taking naltrexone reported significantly less alcohol craving and days in which any alcohol was consumed. During the 12-week study, only 23% of the naltrexone-treated subjects met the criteria for a relapse, whereas 54.3% of the placebo-treated subjects relapsed. The primary effect of naltrexone was seen in patients who drank any alcohol while attending outpatient treatment. Nineteen (95%) of the 20 placebo-treated patients relapsed after they sampled alcohol, while only eight (50%) of 16 naltrexone-treated patients exposed to alcohol met relapse criteria. Naltrexone was not associated with mood changes or other psychiatric symptoms. Significant side effects (nausea) occurred in two naltrexone-treated subjects, and one naltrexone-treated subject complained of increased pain from arthritis. These results suggest that naltrexone may be a safe and effective adjunct to treatment in alcohol-dependent subjects, particularly in preventing alcohol relapse.

Integrity signals

Registry

Crossref · 10.1001/archpsyc.1992.01820110040006

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory
Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., & Covi, L. (1974) · Behavioral Science · doi:10.1002/bs.3830190102 · Cited by 4,604
Survival Analysis
Miller, R. G. (1981) · Cited by 3,336
Disulfiram treatment of alcoholism. A Veterans Administration cooperative study
Fuller, R. K. (1986) · JAMA · doi:10.1001/jama.256.11.1449 · Cited by 541
Alteration of ethanol self-administration by naltrexone
Altshuler, H. L., Phillips, P. E., & Feinhandler, D. A. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90257-x · Cited by 397
The Effectiveness of Alcoholism Treatment
Miller, W. R., & Hester, R. K. (1986) · Springer eBooks · doi:10.1007/978-1-4613-2191-0_7 · Cited by 276
The serotonin uptake inhibitor citalopram attenuates ethanol intake
Naranjo, C. A., Sellers, E. M., Sullivan, J. T., Woodley-Remus, D., Kadlec, K. E., & Sykora, K. (1987) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1987.27 · Cited by 236
Naltrexone blocks the post-shock increase of ethanol consumption
Volpicelli, J. R., Davis, M. A., & Olgin, J. E. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90601-6 · Cited by 187
Self-citation
Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey
Myers, R. D., Borg, S., & Mossberg, R. (1986) · Alcohol · doi:10.1016/0741-8329(86)90058-3 · Cited by 167
Lithium Treatment of Depressed and Nondepressed Alcoholics
Dorus, W. (1989) · JAMA · doi:10.1001/jama.1989.03430120100029 · Cited by 164
Oral ethanol self-administration in the rat: Effect of naloxone
Samson, H. H., & Doyle, T. F. (1985) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(85)90491-5 · Cited by 162

Show all 23 references

Sorted by citations

Items 201–300 of 1,004

Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers
Drobes, D. J., Anton, R. F., Thomas, S. E., & Voronin, K. (2004) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000139704.88862.01 · Cited by 140
Reduction in heavy drinking as a treatment outcome in alcohol dependence
Gastfriend, D. R., Garbutt, J. C., Pettinati, H. M., & Forman, R. F. (2007) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.09.008 · Cited by 139
Behavioral couples treatment of alcohol and drug use disorders
Epstein, E. E., & McCrady, B. S. (1998) · Clinical Psychology Review · doi:10.1016/s0272-7358(98)00025-7 · Cited by 140
Attenuation of alcohol intake by Ibogaine in three strains of alcohol-preferring rats
Rezvani, A. H., Overstreet, D. H., & Leef, Y.-W. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)00152-m · Cited by 139
A Comparison of the Effects of the Opioid Antagonists Naltrexone, Naltrindole, and β-Funaltrexamine on Ethanol Consumption in the Rat
Stromberg, M. F., Casale, M., Volpicelli‐Daley, L. A., Volpicelli, J. R., & O’Brien, C. P. (1998) · Alcohol · doi:10.1016/s0741-8329(97)00131-6 · Cited by 139
Self-citation
Naltrexone and relapse prevention treatment for cocaine-dependent patients
Schmitz, J. M., Stotts, A. L., Rhoades, H. M., & Grabowski, J. (2001) · Addictive Behaviors · doi:10.1016/s0306-4603(00)00098-8 · Cited by 138
Impulsivity and Substance Abuse: What Is the Connection?
Moeller, F. G., & Dougherty, D. M. (2002) · Addictive Disorders & Their Treatment · doi:10.1097/00132576-200205000-00002 · Cited by 146
Self-administration of cannabinoids by experimental animals and human marijuana smokers
Justinová, Z., Goldberg, S. R., Heishman, S. J., & Tanda, G. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.026 · Cited by 137
State-of-the-art behavioral and pharmacological treatments for alcohol use disorder
Ray, L. A., Bujarski, S., Grodin, E. N., Hartwell, E. E., Green, R., Venegas, A., Lim, A. C., Gillis, A. J., & Miotto, K. A. (2018) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1528265 · Cited by 136
Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: Temporal effects of drinking
Anton, R. F., Drobes, D. J., Voronin, K., Durazo-Avizu, R., & Moak, D. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1720-7 · Cited by 135
OPRM1 SNP (A118G): Involvement in disease development, treatment response, and animal models
Mague, S. D., & Blendy, J. A. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.12.016 · Cited by 138
Moderators of Naltrexone’s Effects on Drinking, Urge, and Alcohol Effects in Non‐Treatment‐Seeking Heavy Drinkers in the Natural Environment
Tidey, J. W., Monti, P. M., Rohsenow, D. J., Gwaltney, C. J., Miranda, R., McGeary, J. E., MacKillop, J. M., Swift, R. M., Abrams, D. B., Shiffman, S. M., et al. (2007) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00545.x · Cited by 137
Involvement of μ-opioid receptors in alcohol drinking by alcohol-preferring AA rats
Hyytiä, P. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90527-z · Cited by 136
κ-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats
Nealey, K. A., Smith, A. W., Davis, S. M., Smith, D. G., & Walker, B. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.012 · Cited by 133
Sex hormone activity in alcohol addiction: Integrating organizational and activational effects
Lenz, B., Müller, C. P., Stoessel, C., Sperling, W., Biermann, T., Hillemacher, T., Bleich, S., & Kornhuber, J. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.11.001 · Cited by 145
Dissociation of "conscious desire" (craving) from and relapse in alcohol and cocaine dependence.
Miller, N. S., & Gold, M. (1994) · Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists · doi:10.3109/10401239409148988 · Cited by 141
How Many Cravings? Pharmacological Aspects of Craving Treatment in Alcohol Addiction: A Review
Addolorato, G., Abenavoli, L., Leggio, L., & Gasbarrini, A. (2005) · Neuropsychobiology · doi:10.1159/000084161 · Cited by 133
Selective effects of naltrexone on food pleasantness and intake
Yeomans, M. R., & Gray, R. W. (1996) · Physiology & Behavior · doi:10.1016/s0031-9384(96)80017-5 · Cited by 133
Acamprosate treatment in a long-term community-based alcohol rehabilitation programme
Poldrugo, F. (1997) · Addiction · doi:10.1111/j.1360-0443.1997.tb02873.x · Cited by 133
Opioid antagonists for smoking cessation
David, S. P., Lancaster, T., Stead, L. F., Evins, A. E., & Prochaska, J. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003086.pub3 · Cited by 132
Neuronal Nicotinic Acetylcholine Receptors: Common Molecular Substrates of Nicotine and Alcohol Dependence
Hendrickson, L. M., Guildford, M. J., & Tapper, A. R. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00029 · Cited by 140
Evaluation of the “Pipeline” for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research
Czoty, P. W., Stoops, W. W., & Rush, C. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011668 · Cited by 131
Effect of nociceptin on alcohol intake in alcohol-preferring rats
Ciccocioppo, R., Panocka, I., Polidori, C., Regoli, D. C., & Massi, M. (1999) · Psychopharmacology · doi:10.1007/s002130050828 · Cited by 130
Compulsive features in behavioural addictions: the case of pathological gambling
el‐Guebaly, N., Mudry, T., Zohar, J., Tavares, H., & Potenza, M. N. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03546.x · Cited by 140
A Randomized Clinical Trial of Alcohol Care Management Delivered in Department of Veterans Affairs Primary Care Clinics Versus Specialty Addiction Treatment
Oslin, D. W., Lynch, K. G., Maisto, S. A., Lantinga, L. J., McKay, J. R., Possemato, K., Ingram, E. P., & Wierzbicki, M. R. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2625-8 · Cited by 128
PHARMACOTHERAPIES FOR ALCOHOL ABUSE
Saitz, R., & O’Malley, S. S. (1997) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70554-x · Cited by 130
Single‐ and Multiple‐Dose Pharmacokinetics of Long‐acting Injectable Naltrexone
Dunbar, J., Turncliff, R. Z., Dong, Q., Silverman, B. L., Ehrich, E. W., & Lasseter, K. C. (2006) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2006.00052.x · Cited by 129
Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence.
Tomkins, D. M., & Sellers, E. M. (2001) · Europe PMC (PubMed Central) · Cited by 129
ESBRA-NORDMANN 1996 AWARD LECTURE: ETHANOL DRINKING BEHAVIOUR IN SARDINIAN ALCOHOL-PREFERRING RATS
Colombo, G. (1997) · Alcohol and Alcoholism · doi:10.1093/oxfordjournals.alcalc.a008279 · Cited by 129
Lack of Efficacy of Naltrexone in the Prevention of Alcohol Relapse: Results From a German Multicenter Study
Gastpar, M., Bonnet, U., Böning, J., Mann, K. F., Schmidt, L., Soyka, M., Wetterling, T., Kielstein, V., Labriola, D., & Croop, R. S. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200212000-00009 · Cited by 129
Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double‐Blind Placebo‐Controlled Multicenter Study
Karhuvaara, S., Simojoki, K., Virta, A., Rosberg, M., Löyttyniemi, E., Nurminen, T., Kallio, A., & Mäkelä, R. (2007) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00401.x · Cited by 127
Pharmacotherapy of Alcohol Use Disorders: Seventy-Five Years of Progress
Zindel, L. R., & Kranzler, H. R. (2014) · Journal of Studies on Alcohol and Drugs Supplement · doi:10.15288/jsads.2014.s17.79 · Cited by 128
Early recovery from alcohol dependence: factors that promote or impede abstinence.
Charney, D., Zikos, E., & Gill, K. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2009.06.002 · Cited by 122
Comorbidity of Alcoholism and Psychiatric Disorders: An Overview
Petrakis, I. L., Gonzalez, G. M., Rosenheck, R. A., & Krystal, J. H. (2002) · Europe PMC (PubMed Central) · Cited by 127
Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting
Latt, N. C., Jurd, S. M., Houseman, J., & Wutzke, S. E. (2002) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2002.tb04550.x · Cited by 128
Making a bad thing worse: adverse effects of stress on drug addiction
Cleck, J. N., & Blendy, J. A. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33946 · Cited by 122
Barriers to the Use of Medications to Treat Alcoholism
Mark, T. L., Kranzler, H. R., Poole, V. H., Hagen, C. A., McLeod, C. C., & Crosse, S. B. (2003) · American Journal on Addictions · doi:10.1080/10550490390226879 · Cited by 126
Cannabinoid Receptor 1 Blocker Rimonabant (SR 141716) for Treatment of Alcohol Dependence
Soyka, M., Koller, G., Schmidt, P., Lesch, O., Leweke, F. M., Fehr, C., Gann, H., & Mann, K. F. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b8bc · Cited by 129
Pharmacological validation of a new animal model of alcoholism
Spanagel, R., & Hölter, S. M. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070068 · Cited by 126
Feeding, drug abuse, and the sensitization of reward by metabolic need
Carr, K. D. (1996) · Neurochemical Research · doi:10.1007/bf02532386 · Cited by 124
The Effects of Acamprosate and Neramexane on Cue-Induced Reinstatement of Ethanol-Seeking Behavior in Rat
Bachteler, D., Economidou, D., Danysz, W., Ciccocioppo, R., & Spanagel, R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300657 · Cited by 125
Prevention of sudden unexpected death in epilepsy: A realistic goal?
Ryvlin, P., Nashef, L. A. M., & Tomson, T. (2013) · Epilepsia · doi:10.1111/epi.12180 · Cited by 124
Ethanol-Induced Conditioned Place Preference Is Expressed Through a Ventral Tegmental Area Dependent Mechanism.
Bechtholt, A. J., & Cunningham, C. L. (2005) · Behavioral Neuroscience · doi:10.1037/0735-7044.119.1.213 · Cited by 124
Evidence-based treatments of addiction
O’Brien, C. P. (2008) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2008.0105 · Cited by 130
Experience of a "slip" among alcoholics treated with naltrexone or placebo
O’Malley, S. S., Jaffe, A. J., Rode, S., & Rounsaville, B. J. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.2.281 · Cited by 123
Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence
Anton, R. F., Moak, D. H., Latham, P., Waid, L. R., Myrick, H., Voronin, K., Thevos, A., Wang, W., & Woolson, R. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000172071.81258.04 · Cited by 121
Improving Naltrexone Response
Pettinati, H. M., Volpicelli, J. R., Pierce, J. D., & O’Brien, C. P. (2000) · Journal of Addictive Diseases · doi:10.1300/j069v19n01_06 · Cited by 122
Self-citation
Effect of chronic alcohol consumption on the activity of the hypothalamic-pituitary-adrenal axis and pituitary beta-endorphin as a function of alcohol intake, age, and gender.
Gianoulakis, C., Dai, X., & Brown, T. (2003) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000056614.96137.b8 · Cited by 115
Understanding US addiction physicians' low rate of naltrexone prescription
Mark, T. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00134-0 · Cited by 120
Animal models of alcohol's motivational effects.
Cunningham, C., Fidler, T. L., & Hill, K. (2000) · PubMed Central · Cited by 121
Physicians’ opinions about medications to treat alcoholism
Mark, T. L., Kranzler, H. R., Song, X., Bransberger, P., Poole, V. H., & Crosse, S. B. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00377.x · Cited by 119
The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption
Cowen, M. S., & Lawrence, A. J. (1999) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(99)00060-3 · Cited by 124
Ethanol as a neurochemical surrogate of conventional reinforcers: The dopamine-opioid link
Chiara, G. D., Acquas, E., & Tanda, G. (1996) · Alcohol · doi:10.1016/0741-8329(95)02034-9 · Cited by 117
A Multi-site Dose Ranging Study of Nalmefene in the Treatment of Alcohol Dependence
Anton, R. F., Pettinati, H. M., Zweben, A., Kranzler, H. R., Johnson, B. A., Bohn, M. J., McCaul, M. E., Anthenelli, R. M., Salloum, I. M., Galloway, G. P., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000130555.63254.73 · Cited by 117
Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia
Petrakis, I. L., O’Malley, S. S., Rounsaville, B. J., Poling, J. C., McHugh-Strong, C., & Krystal, J. H. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1658-9 · Cited by 119
Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence.
Franke, P. E., Wang, T., Nöthen, M. M., Knapp, M., Neidt, H., Albrecht, S., Jahnes, E., Propping, P., & Maier, W. (2001) · PubMed · Cited by 119
Family History of Alcoholism and Hypothalamic Opioidergic Activity
Wand, G. S., Mangold, D. L., El-Deiry, S., McCaul, M. E., & Hoover, D. R. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1114 · Cited by 118
Naltrexone vs Placebo for the Treatment of Alcohol Dependence
Oslin, D. W., Leong, S. H., Lynch, K. G., Berrettini, W. H., O’Brien, C. P., Gordon, A. J., & Rukstalis, M. R. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.3053 · Cited by 121
Sustained‐Release Naltrexone for Alcoholism Treatment: A Preliminary Study
Kranzler, H. R., Modesto‐Lowe, V., & Nuwayser, E. S. (1998) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1998.tb03703.x · Cited by 118
Translating the neuroscience of alcoholism into clinical treatments: From blocking the buzz to curing the blues
Heilig, M., Thorsell, A., Sommer, W. H., Hansson, A. C., Ramchandani, V. A., George, D. T., Hommer, D., & Barr, C. S. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.11.018 · Cited by 117
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta‐analysis
Donoghue, K., Zerbi, C. E., Saunders, R., Whittington, C. J., Pilling, S., & Drummond, C. (2015) · Addiction · doi:10.1111/add.12875 · Cited by 117
A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial.
Guardia, J., Caso, C., Árias, F., Gual, A., Sanahuja, J., Ramírez, M., Mengual, I., Gonzalvo, B., Segura, L., Trujols, J., et al. (2002) · PubMed · doi:10.1097/01.alc.0000030561.15921.a9 · Cited by 117
A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence.
Mueller, T. I., Stout, R. L., Rudden, S., Brown, R. A., Gordon, A. A., Solomon, D. A., & Recupero, P. R. (1997) · PubMed · Cited by 117
Food Cravings, Endogenous Opioid Peptides, and Food Intake: A Review
Mercer, M. E., & Holder, M. D. (1997) · Appetite · doi:10.1006/appe.1997.0100 · Cited by 116
The selective κ-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat
Lindholm, S., Werme, M., Brené, S., & Franck, J. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00368-5 · Cited by 116
NALTREXONE VERSUS ACAMPROSATE: ONE YEAR FOLLOW-UP OF ALCOHOL DEPENDENCE TREATMENT
Rubio, G. (2001) · Alcohol and Alcoholism · doi:10.1093/alcalc/36.5.419 · Cited by 116
Alcohol Potentiates Hepatitis C Virus Replicon Expression
Zhang, T., Li, Y., Lai, J.-P., Douglas, S. D., Metzger, D. S., O'Brien, C. P., & Ho, W. (2003) · Hepatology · doi:10.1053/jhep.2003.50295 · Cited by 116
Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats
Hölter, S. M., & Spanagel, R. (1999) · Psychopharmacology · doi:10.1007/s002130051069 · Cited by 114
A Double‐Blind, Placebo‐Controlled Pilot Study of Carbamazepine for the Treatment of Alcohol Dependence
Mueller, T. I., Stout, R. L., Rudden, S., Brown, R. A., Gordon, A. A., Solomon, D. A., & Recupero, P. R. (1997) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1997.tb03733.x · Cited by 115
Interpreting the significance of drinking by alcohol-dependent liver transplant patients: Fostering candor is the key to recovery
Weinrieb, R. M., Horn, D. H. A. V., McLellan, A. T., & Lucey, M. R. (2000) · Liver Transplantation · doi:10.1053/jlts.2000.18497 · Cited by 113
The delta2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference
Krishnan‐Sarin, S., Portoghese, P. S., Li, T., & Froehlich, J. C. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)00080-g · Cited by 112
Pharmacogenetics of OPRM1
Crist, R. C., & Berrettini, W. H. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.10.018 · Cited by 115
The opioid antagonist naltrexone reduces the reinforcing effects of ? 9 -tetrahydrocannabinol (THC) in squirrel monkeys
Tanda, G., Munzar, P., Goldberg, S. R., & Justinova, Z. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1693-6 · Cited by 111
Pharmacological Relapse Prevention of Alcoholism: Clinical Predictors of Outcome
Kiefer, F., Helwig, H., Tarnaske, T., Otte, C., Jahn, H., & Wiedemann, K. (2005) · European Addiction Research · doi:10.1159/000083037 · Cited by 106
Evidence-based practices for substance use disorders
McGovern, M. P., & Carroll, K. M. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(03)00073-x · Cited by 118
A Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Acamprosate and Naltrexone
Mason, B. J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00368-8 · Cited by 110
Naltrexone Alters Subjective and Psychomotor Responses to Alcohol in Heavy Drinking Subjects
McCaul, M. E. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00147-5 · Cited by 111
Naltrexone Increases the Latency to Drink Alcohol in Social Drinkers
Davidson, D., Swift, R. M., & Fitz, E. (1996) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1996.tb01679.x · Cited by 111
Effects of CRF 1 ‐Receptor and Opioid‐Receptor Antagonists on Dependence‐Induced Increases in Alcohol Drinking by Alcohol‐Preferring (P) Rats
Gilpin, N. W., Richardson, H. N., & Koob, G. F. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00745.x · Cited by 114
The effects of selective blockade of delta and mu opiate receptors on ethanol consumption by C57BL/6 mice in a restricted access paradigm
Lê, A. D., Poulos, C. X., Quan, B., & Chow, S. (1993) · Brain Research · doi:10.1016/0006-8993(93)90672-a · Cited by 110
Developing Performance Measures for Alcohol and Other Drug Services in Managed Care Plans
McCorry, F., Garnick, D. W., Bartlett, J., Cotter, F., Chalk, M., Babor, T. F., Falcon, S., Gastfriend, D. R., Gelber, S., Harrison, P. A., et al. (2000) · The Joint Commission Journal on Quality Improvement · doi:10.1016/s1070-3241(00)26054-9 · Cited by 110
Effect of Mu Opioid Receptor Blockade on Alcohol Intake in Rats Bred for High Alcohol Drinking
Krishnan‐Sarin, S., Wand, G. S., Li, X.-W., Portoghese, P. S., & Froehlich, J. C. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00474-7 · Cited by 110
Addiction: brain mechanisms and their treatment implications
Nutt, D. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91561-5 · Cited by 110
Pharmacotherapy for alcohol dependence: status of current treatments
Franck, J., & Jayaram-Lindström, N. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.05.005 · Cited by 107
The 10 most important things known about addiction
Sellman, D. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02673.x · Cited by 137
Medical Treatment of Alcohol Dependence: A Systematic Review
Miller, P. M., Book, S. W., & Stewart, S. (2011) · The International Journal of Psychiatry in Medicine · doi:10.2190/pm.42.3.b · Cited by 114
The neurobiology of addiction: an overview.
Roberts, A. J., & Koob, G. F. (1997) · PubMed Central · Cited by 109
Alcoholism: the role of different motivational systems.
Pihl, R. O., & Peterson, J. B. (1995) · PubMed Central · Cited by 109
Management of Alcohol Dependence in Patients with Liver Disease
Addolorato, G., Mirijello, A., Leggio, L., Ferrulli, A., & Landolfi, R. (2013) · CNS Drugs · doi:10.1007/s40263-013-0043-4 · Cited by 113
Pharmacotherapy of Alcohol Use Disorders by the Veterans Health Administration: Patterns of Receipt and Persistence
Harris, A. H. S., Oliva, E. M., Bowe, T. R., Humphreys, K. N., Kivlahan, D. R., & Trafton, J. A. (2012) · Psychiatric Services · doi:10.1176/appi.ps.201000553 · Cited by 110
Association of a Functional Polymorphism in the μ-Opioid Receptor Gene With Alcohol Response and Consumption in Male Rhesus Macaques
Barr, C. S., Schwandt, M., Lindell, S. G., Chen, S. A., Goldman, D., Suomi, S. J., Higley, J. D., & Heilig, M. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.369 · Cited by 105
Acute effects of Naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice
Kamdar, N., Miller, S. A., Syed, Y. M., Bhayana, R., Gupta, T., & Rhodes, J. S. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0711-5 · Cited by 108
Naltrexone Attenuates the Subjective Effects of Amphetamine in Patients with Amphetamine Dependence
Jayaram‐Lindström, N., Konstenius, M., Eksborg, S., Beck, O., Hammarberg, A., & Franck, J. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301572 · Cited by 107
Recent animal models of alcoholism.
Spanagel, R. (2000) · PubMed Central · Cited by 107
Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European‐Americans
Luο, X., Kranzler, H. R., Zhao, H., & Gelernter, J. E. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20034 · Cited by 108
Pharmacotherapy of Alcohol Use Disorders in the Veterans Health Administration
Harris, A. H. S., Kivlahan, D. R., Bowe, T. R., & Humphreys, K. N. (2010) · Psychiatric Services · doi:10.1176/ps.2010.61.4.392 · Cited by 107
Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence
Walker, B. M., Valdez, G. R., McLaughlin, J. P., & Bakalkin, G. Y. (2012) · Alcohol · doi:10.1016/j.alcohol.2011.10.006 · Cited by 107
PHARMACOTHERAPY OF ALCOHOLISM: GAPS IN KNOWLEDGE AND OPPORTUNITIES FOR RESEARCH
Kranzler, H. R. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.6.537 · Cited by 106
Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users
Quinn, D. I., Wodak, A., & Day, R. O. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733050-00003 · Cited by 106
Single‐nucleotide polymorphism (A118G) in exon 1 ofOPRM1gene causes alteration in downstream signaling by mu‐opioid receptor and may contribute to the genetic risk for addiction
Deb, I., Chakraborty, J., Gangopadhyay, P. K., Choudhury, S. R., & Das, S. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06472.x · Cited by 105

Authors: Volpicelli, J. R.
Affiliations: University of Pennsylvania (US)
Corresponding author: Volpicelli, Joseph R.
ORCID: Volpicelli, Joseph R.
Venue: Archives of General Psychiatry
Publisher: American Medical Association (AMA)
Published: 1992-11-01
Volume: 49
Issue: 11
Pages: 876
ISSN: 0003-990X (ISSN-L)
DOI: 10.1001/archpsyc.1992.01820110040006
OpenAlex: W2104538950
Cited by: 1,828
References: 23
Citations by year: 2026: 7 · 2025: 10 · 2024: 17 · 2023: 15 · 2022: 25 · 2021: 17 · 2020: 28 · 2019: 26 · 2018: 29 · 2017: 26 · 2016: 32 · 2015: 48 · 2014: 49 · 2013: 47 · 2012: 58
FWCI: 36.57
Type: journal article
Language: en
Open access: closed
Locations: Archives of General Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (AA0751701A1)
National Institute on Drug Abuse (DA-05186)
Topics: Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
Keywords: naltrexone, alcoholism, alcohol craving, alcohol relapse prevention, alcohol detoxification, outpatient care, opioid antagonists, adjunct pharmacotherapy, nausea, arthritic pain
MeSH terms: Adult, Alcohol Drinking, Alcoholism, Ambulatory Care, Combined Modality Therapy, Double-Blind Method, Humans, Male, Naltrexone, Nausea, Patient Dropouts, Placebos, Psychiatric Status Rating Scales, Psychotherapy, Recurrence, Severity of Illness Index, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Naltrexone in the Treatment of Alcohol Dependence

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks